Released Nov 5, 2026, after the close
10-Q filed Nov 5, 2026, 36 days after period end · 0001628280-26-071056
The Company also raised its full-year guidance.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $371.07M | $377.43M | $314.39M | $262.74M |
| Net Income | $18.68M | $9.82M | -$121.99M | -$7.00M |
Guardian Pharmacy Services, Inc. · CIK 1802255 · Engraved from SEC EDGAR
| EPS Diluted | $0.29 | $0.15 | — | — |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adjusted EBITDA for the third quarter was $33.9 million, up 24% year-over-year, and diluted EPS was $0.29 with Adjusted EPS of $0.33.¶2¶3
Guardian raised its FY 2026 guidance, which excludes future acquisitions, to revenue of $1.44 billion -$1.46 billion from $1.43 billion - $1.45 billion and Adjusted EBITDA of $136 million - $138 million from $129 million - $131 million.¶4¶5¶6
Guardian completed the acquisition of Wellness Concepts in July, and completed the acquisition of Van's Institutional Pharmacy earlier in the week of the release.¶7¶8
Approximately 13.5 million Class B shares converted into Class A common stock on September 27, 2026, and lock-up agreements covering approximately 29.9 million shares remain in effect through September 14, 2027.¶9¶10